Sunder Biomedical Tech. , Ltd. Overview
Valuation check: 4115.TWO's ROE is -0.57%, below the sector sector average of 11.73%.
Get informed when a big investor buys or sells
+ Follow-0.57%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 4115.TWO is -0.57%. That is below the sector sector average of 11.73%. Investors often review this figure alongside Sunder Biomedical Tech. , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 4115.TWO currently prints -0.57% for ROE, while the sector average sits near 11.73%. That is roughly 104.8% below the sector mean. Large gaps often invite a closer look at Sunder Biomedical Tech. , Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Sunder Biomedical Tech. , Ltd. converts resources into returns. At -0.57%, 4115.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 4115.TWO's ROE (-0.57%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
